203 related articles for article (PubMed ID: 11508904)
1. The performance and problems of the Turkish pharmaceutical industry: is there a need to develop a national drug policy?
Kisa A
J Med Syst; 2001 Oct; 25(5):309-18. PubMed ID: 11508904
[TBL] [Abstract][Full Text] [Related]
2. Taking TRIPS to India--Novartis, patent law, and access to medicines.
Mueller JM
N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
[No Abstract] [Full Text] [Related]
3. Reprivatizing pharmaceutical supplies in Africa.
Turshen M
J Public Health Policy; 2001; 22(2):198-225. PubMed ID: 11469153
[TBL] [Abstract][Full Text] [Related]
4. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
Bird RC
J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
[TBL] [Abstract][Full Text] [Related]
5. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
6. Improving access to medicines in poor countries: the role of universities.
Chokshi DA
PLoS Med; 2006 Apr; 3(6):e136. PubMed ID: 16608382
[TBL] [Abstract][Full Text] [Related]
7. Access to essential drugs, human rights and global justice.
Shalev C
Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
[No Abstract] [Full Text] [Related]
8. Expanding drug access in Brazil: lessons for Latin America and Canada.
Cohen JC
Can J Public Health; 2006; 97(6):I15-8. PubMed ID: 17203728
[TBL] [Abstract][Full Text] [Related]
9. World pharmaceutical developments.
Bale H
World Hosp Health Serv; 2002; 38(2):1. PubMed ID: 12402745
[No Abstract] [Full Text] [Related]
10. Policy watch. Profitable pills.
Gebbie KM
AIDS Read; 2004 Mar; 14(3):106, 109. PubMed ID: 15067998
[No Abstract] [Full Text] [Related]
11. No deal in sight on cheap drugs for poor countries.
Fleck F
Bull World Health Organ; 2003; 81(4):307-8. PubMed ID: 12764500
[No Abstract] [Full Text] [Related]
12. Eliminating neglected diseases: impact of published paper.
Brownback S
Health Aff (Millwood); 2007; 26(5):1509. PubMed ID: 17848471
[No Abstract] [Full Text] [Related]
13. Academic patents and access to medicines in developing countries.
Sampat BN
Am J Public Health; 2009 Jan; 99(1):9-17. PubMed ID: 19008514
[TBL] [Abstract][Full Text] [Related]
14. Innovation and the WHO's essential medicines list: giving credit where credit is due.
Wertheimer AI; Santella TM
Res Social Adm Pharm; 2007 Mar; 3(1):137-44. PubMed ID: 17350562
[No Abstract] [Full Text] [Related]
15. Access to critical medicines: When are compulsory licenses effective in price negotiations?
Ramani SV; Urias E
Soc Sci Med; 2015 Jun; 135():75-83. PubMed ID: 25957163
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug use in Bangladesh: policy versus practice.
Islam MS
Indian J Med Ethics; 2008; 5(1):24-5. PubMed ID: 18630250
[TBL] [Abstract][Full Text] [Related]
17. Vaccine supply, demand, and policy: a primer.
Muzumdar JM; Cline RR
J Am Pharm Assoc (2003); 2009; 49(4):e87-99. PubMed ID: 19589753
[TBL] [Abstract][Full Text] [Related]
18. Shortages of inexpensive essential medicines.
Vyas M; de Vries EGE; Casali PG; Tabernero J
Lancet Oncol; 2019 May; 20(5):e224-e225. PubMed ID: 31006527
[No Abstract] [Full Text] [Related]
19. EU launches measures to stop diversion of cut-price drugs.
Fleck F
Bull World Health Organ; 2003; 81(7):549. PubMed ID: 12973652
[No Abstract] [Full Text] [Related]
20. [Access for all to quality drugs].
Videau JY
Med Trop (Mars); 2002; 62(4):396-400. PubMed ID: 12534178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
